LYNX1 CAPITAL MANAGEMENT LP purchased 2.1% of their position (161.80K shares) of TSCAN THERAPEUTICS, INC. on the open market
Open‑market purchase worth $145.5K — a small addition. The strongest form of insider conviction signal.
P · 3 purchases
Filed: 12/23/2025ACC: 0000902664-25-005396
10% Owner
Since May 2023
+161.80K
Net shares
Net buyer
$145.5K
Total acquired
3
Open market trades
3B · 0S
3
Total transactions
161.80K acquired
Non-Derivative Transactions3
Common stock, $0.0001 par value per share ("Common Stock")
Indirect
Shares
+80.07K
Price / share
$0.90
Trade value
$71.97K
% of position
1.0%
12/19/2025
7.86M→7.94M
Common Stock
Indirect
Shares
+75.50K
Price / share
$0.90
Trade value
$67.95K
% of position
1.0%
12/22/2025
7.94M→8.01M
Common Stock
Indirect
Shares
+6.23K
Price / share
$0.90
Trade value
$5.60K
% of position
0.1%
12/23/2025
8.01M→8.02M
Total
Net shares
+161.80K
Net value
$145.53K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.0001 par value per share ("Common Stock") Indirect | 12/19/2025 | P · Purchase | +80.07K | $0.90 | $71.97K | 1.0% | 7.86M | 7.94M |
| Common Stock Indirect | 12/22/2025 | P · Purchase | +75.50K | $0.90 | $67.95K | 1.0% | 7.94M | 8.01M |
| Common Stock Indirect | 12/23/2025 | P · Purchase | +6.23K | $0.90 | $5.60K | 0.1% | 8.01M | 8.02M |
| Total | +161.80K | $145.53K | ||||||
Derivative Transactions0
No derivative transactions reported